Cuba's tobacco finds use in vaccine purification

By Gregory Roumeliotis

- Last updated on GMT

Related tags: Biotechnology

The first ever monoclonal antibody obtained starting from
transgenic plants with the purpose of purifying a human vaccine has
been registered with Cuban authorities, meaning cigars may not be
the only application the country's tobacco is used for in the

The country's official news agency reported the antibody is used in the process of purifying the active pharmaceutical ingredient (API) of the Hepatitis B vaccine produced in Cuba by Havana's Genetic Engineering and Biotechnology Center (CIGB), sold under the trademark of Heberbiovac-HB.

CIGB scientists say obtaining the antibody from genetically modified tobacco plants, has advantages over the traditional process of starting from the ascitic liquid of the mouse, due to higher levels of safety and production.

They also stress that tobacco plantations that are genetically modified have nothing to do with the commercial strains of that plant and that the CIGB has taken appropriate actions to avoid possible risks to the environment when cultivating engineered strains.

This production process is confined to special controlled growing areas where the technology specifically created with that purpose is in use, according to the good agricultural production practices demanded in the obtaining of vegetable biomass for pharmaceutical applications, the CIGB said.

The monoclonal antibody obtained from transgenic plants obtained the license from the National Center of Biological Safety that is part of the Cuban Ministry of Science, Technology and the Environment.

Be it recombinant proteins in milk, polyclonal antibodies in eggs or digestive enzymes in corn, the potential of transgenic animals and plants for the cheap and efficient production of biopharmaceuticals is huge, potentially leading to sales of more than $12bn (€10bn) by 2012 according to market research firm Kalorama.

However, due to the practical difficulties involved, big pharma has been apprehensive about transgenic drugs even before the ruling and despite the significant savings and reliability that transgenic technology promises.

Related news

Show more

Related products

show more

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more